Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.
暂无分享,去创建一个
I. Sesterhenn | M. Coel | S. Kwee | Isabell Sesterhenn | Sandi A Kwee | Hai Wei | David Yun | Marc N Coel | Hai-liang Wei | David Yun
[1] R. Coleman,et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. , 2002, The Journal of urology.
[2] R. Coleman,et al. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] C C Ling,et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.
[4] Mary Ann Moran,et al. Synthesis and Evaluation , 1986 .
[5] L. Adler,et al. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. , 1997, Journal of nuclear medicine technology.
[6] T. Hara,et al. PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] A. Fowler,et al. Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR , 1992, Magnetic resonance in medicine.
[8] J. Nelson,et al. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. , 2001, Cancer research.
[9] P. Carroll,et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.
[10] M. Coel,et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. , 2005, The Journal of urology.
[11] A. Heerschap,et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. , 1993, The Journal of urology.
[12] L Verhey,et al. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. , 1999, International journal of radiation oncology, biology, physics.
[13] J. Kurhanewicz,et al. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer , 2002, Journal of magnetic resonance imaging : JMRI.
[14] R. Rosell,et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.
[15] W. Fair,et al. Incidence and clinical significance of false-negative sextant prostate biopsies. , 1998, The Journal of urology.
[16] R. Coleman,et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] G. V. von Schulthess,et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.
[18] Y. Soini,et al. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern‐blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies , 1993, International journal of cancer.
[19] E J Halpern,et al. Imaging prostate cancer: current and future applications. , 2001, Oncology.
[20] Z. Bhujwalla,et al. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. , 1999, Cancer research.
[21] J. Fracchia,et al. Influence of prostate volume in the detection of prostate cancer. , 2003, Urology.
[22] J. Pouliot,et al. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. , 2004, International journal of radiation oncology, biology, physics.
[23] J Kurhanewicz,et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. , 2000, The Journal of urology.
[24] M. van der Graaf,et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. , 1997, Anticancer research.
[25] T. Hara,et al. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] D. Ornstein,et al. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. , 2000, The Journal of urology.
[27] M. Coel,et al. Combined Use of F‐18 Fluorocholine Positron Emission Tomography and Magnetic Resonance Spectroscopy for Brain Tumor Evaluation , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.